ChemicalBook Product Catalog Biochemical Engineering Plant extracts dryocrassin

dryocrassin

Product Namedryocrassin
CAS12777-70-7
MFC43H48O16
MW820.83
EINECS
MOL File12777-70-7.mol

Chemical Properties

Boiling point	1089.0±65.0 °C(Predicted)
Density	1.474±0.06 g/cm3 (20 ºC 760 Torr)
solubility	Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
form	powder
pka	4.20±1.00(Predicted)
color	Yellow

Usage And Synthesis

Uses

Dryocrassin ABBA (Dryocrassin) is an orally active phloroglucinol derivative that can be extracted from Phyllopteris officinalis. Dryocrassin ABBA has antitumor and antiviral activity. Dryocrassin ABBA induced apoptosis of human hepatocellular carcinoma cells through mitochondrial pathway mediated by Caspase[1][2].

Biological Activity

Dryocrassin is a flavonoid natural product, a phloroglucinol derivative derived from Dryopteris crassirhizoma, with antiviral and antibacterial activities. Biological and pharmacological activities of dryocrassin have attracted attention. Dryocrassin exhibits antiviral activity against H5N1 avian influenza virus. Dryocrassin inhibits the coagulase activity of Staphylococcus aureus vWbp. Dryocrassin suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival.

in vivo

Dryocrassin ABBA (Dryocrassin) (0-33 mg/kg; i.g.; daily, 7 days from day 2 to day 8) exerts a significant dose-dependent antiviral effect in mice^[1].
Dryocrassin ABBA (100 mg/kg; s.c.; every 12 h for 96 h) can reduce infection and prevent mice from contracting S. aureus pneumonia^[3].

Animal Model:	SPF BALB/C female mice inoculated intra-nasally with 10^4.5ELD₅₀ H5N1 viruses in 100 μl saline^[1]
Dosage:	33, 18, and 12.5 mg/kg
Administration:	Oral gavage, daily, 7 days from day 2 to day 8
Result:	Significantly reduced mortality, prolonged survival rate, and improved survival time throughout the infection period. Increased body weight and reduced lung lesions and virus loads. Significantly increased MCP-1 and IL-10 while significantly decreased IL-12, IL-6, IFN-γ and TNF-α.

Animal Model:	Eight-week-old C57BL/6J mice infected with 30 μL of S. aureus Newman (2 × 10⁸ CFU/10 μL) by intranasal administration^[3]
Dosage:	100 mg/kg
Administration:	Subcutaneous injection, every 12 h for 96 h
Result:	Resulted a significant increase in survival.

target

References

[1] Ou C, et al. Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus. Front Microbiol. 2015 Jun 16;6:592. DOI:10.3389/fmicb.2015.00592
[2] Ou C, et al. Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus. Front Microbiol. 2015 Jun 16;6:592. DOI:10.3389/fmicb.2015.00592
[3] Jin Z, et al. Dryocrassin ABBA Induces Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells Through a Caspase-Dependent Mitochondrial Pathway. Asian Pac J Cancer Prev. 2016;17(4):1823-8. DOI:10.7314/apjcp.2016.17.4.1823
[4] Zhang B, et al. Molecular Mechanism of the Flavonoid Natural Product Dryocrassin ABBA against Staphylococcus aureus Sortase A. Molecules. 2016 Oct 26;21(11). DOI:10.3390/molecules21111428
[5] Li B, et al. An Inhibitory Effect of Dryocrassin ABBA on Staphylococcus aureus vWbp That Protects Mice From Pneumonia. Front Microbiol. 2019 Jan 23;10:7. DOI:10.3389/fmicb.2019.00007
[6] Fu RH, et al. Dryocrassin suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival. Cell Transplant. 2014;23(4-5):641-56. DOI:10.3727/096368914X678373

dryocrassin

Chemical Properties

Usage And Synthesis

Preparation Products And Raw materials

dryocrassin Supplier

dryocrassin manufacturers

Related articles

Related Product Information